Pixabay/skalecar1992
12 March 2020
The US Food and Drug Administration (FDA) has fast-tracked the approval of artificial intelligence technology that helps to identify babies who are at risk of aggressive posterior retinopathy of prematurity (AP-ROP).
The condition is the most severe form of retinopathy of prematurity with a significant proportion of cases progressing to retinal detachment.
Presenting their research in Ophthalmology, scientists highlighted that babies with AP-ROP are born younger and develop the disease earlier than infants with less severe forms of retinopathy of prematurity.
Lead investigator, Dr J Peter Campbell, highlighted that artificial intelligence has the potential to help recognise babies with AP-ROP earlier.
“It also provides the foundation for quantitative metrics to help us better understand AP-ROP pathophysiology,” he emphasised.
The deep learning system used in the clinical trial, i-ROP DL, has been granted breakthrough status by the FDA. This status accelerates its development and review by the organisation.
The condition is the most severe form of retinopathy of prematurity with a significant proportion of cases progressing to retinal detachment.
Presenting their research in Ophthalmology, scientists highlighted that babies with AP-ROP are born younger and develop the disease earlier than infants with less severe forms of retinopathy of prematurity.
Lead investigator, Dr J Peter Campbell, highlighted that artificial intelligence has the potential to help recognise babies with AP-ROP earlier.
“It also provides the foundation for quantitative metrics to help us better understand AP-ROP pathophysiology,” he emphasised.
The deep learning system used in the clinical trial, i-ROP DL, has been granted breakthrough status by the FDA. This status accelerates its development and review by the organisation.
Comments (0)
You must be logged in to join the discussion. Log in